You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Expanding the Horizons in Hereditary Angioedema: When to Consider Prophylaxis

  • Authors: Marc A. Riedl, MD, MS; Timothy Craig, DO; William R. Lumry, MD
  • CME Released: 11/27/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 11/27/2018
Start Activity


Target Audience and Goal Statement

This activity is intended for allergists, pulmonologists, and primary care physicians.

The goals of this activity are to increase awareness of benefits of long-term prophylaxis for hereditary angioedema (HAE) and treatment options.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Treatment options for long-term prophylaxis of HAE attacks
  • Have greater competence related to
    • Selecting among HAE prophylaxis options based on goals of therapy
    • Patient-centric considerations for short- and long-term HAE prophylaxis


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Marc A. Riedl, MD, MS

    Professor of Medicine, Clinical Director, US HAEA Angioedema Center, Training Program Director , Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, California

    Disclosures

    Disclosure: Marc A. Riedl, MD, MS, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Adverum Biotechnologies; Alnylam Pharmaceuticals, Inc.; BioCryst Pharmaceuticals, Inc.; CSL Behring; Ionis Pharmaceuticals, Inc.; KalVista Pharmaceuticals; Pharming Group NV; Shire
    Served as a speaker or a member of a speakers bureau for: CSL Behring; Pharming Group NV; Shire
    Received grants for clinical research from: BioCryst Pharmaceuticals, Inc.; CSL Behring; Ionis Pharmaceuticals, Inc.; Pharming Group NV; Shire

    Dr Riedl does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Riedl does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • Timothy Craig, DO

    Professor of Medicine and Pediatrics, Distinguished Educator, Program Director, Section Chief, Director of Clinical Allergy, Immunology and Respiratory Research; Director of Alpha-1-Deficiency Center, Vietnam Education Foundation Scholar, Penn State University, Hershey, Pennsylvania

    Disclosures

    Disclosure: Timothy Craig, DO, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BioCryst Pharmaceuticals, Inc.; CSL Behring
    Served as a speaker or a member of a speakers bureau for: CSL Behring; Grifols
    Received grants for clinical research from: BioCryst Pharmaceuticals, Inc.; CSL Behring; Grifols; Shire

    Dr Craig does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Craig does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • William R. Lumry, MD

    Clinical Professor of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical School; Medical Director, AARA Research Center; Private Practice, Dallas, Texas

    Disclosures

    Disclosure: William R. Lumry, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BioCryst Pharmaceuticals, Inc.; CSL Behring; Pharming Group NV; Shire
    Served as a speaker or a member of a speakers bureau for: CSL Behring; Pharming Group NV; Shire

    Dr Lumry does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Lumry does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Susan L. Smith, MN, PhD

    Lead Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Susan L. Smith has disclosed no relevant financial relationships.

CME Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Expanding the Horizons in Hereditary Angioedema: When to Consider Prophylaxis

Authors: Marc A. Riedl, MD, MS; Timothy Craig, DO; William R. Lumry, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 11/27/2017

Valid for credit through: 11/27/2018

processing....

Educational Impact Challenge

The goals of this activity are to increase awareness of benefits of long-term prophylaxis for hereditary angioedema (HAE) and treatment options.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.